Measured Wealth Private Client Group LLC Purchases Shares of 1,826 Krystal Biotech, Inc. $KRYS

Measured Wealth Private Client Group LLC bought a new position in Krystal Biotech, Inc. (NASDAQ:KRYS) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 1,826 shares of the company’s stock, valued at approximately $472,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in KRYS. Soleus Capital Management L.P. lifted its stake in Krystal Biotech by 108.9% during the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock valued at $126,870,000 after buying an additional 481,200 shares in the last quarter. Norges Bank acquired a new position in shares of Krystal Biotech in the fourth quarter worth about $70,159,000. William Blair Investment Management LLC increased its position in shares of Krystal Biotech by 152.1% in the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after acquiring an additional 227,038 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Krystal Biotech by 2,078.9% in the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock worth $54,147,000 after acquiring an additional 209,369 shares in the last quarter. Finally, UBS Group AG raised its holdings in shares of Krystal Biotech by 970.8% during the fourth quarter. UBS Group AG now owns 159,595 shares of the company’s stock valued at $39,347,000 after acquiring an additional 177,922 shares during the period. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Stock Down 0.7%

NASDAQ:KRYS opened at $336.80 on Thursday. The company’s 50 day moving average is $332.97 and its 200-day moving average is $291.66. Krystal Biotech, Inc. has a 12 month low of $130.50 and a 12 month high of $382.54. The firm has a market cap of $9.93 billion, a price-to-earnings ratio of 45.03 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Research analysts predict that Krystal Biotech, Inc. will post 7.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on KRYS shares. Citigroup increased their price objective on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research note on Tuesday, May 5th. Evercore reaffirmed an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research note on Tuesday, May 5th. TD Cowen upped their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Bank of America increased their price target on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Finally, Wall Street Zen cut shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $360.67.

Insider Transactions at Krystal Biotech

In other news, EVP John Charles Thomas sold 1,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 26,642 shares of company stock worth $8,243,923. 13.10% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.